Sudden death in patients with coronary heart disease without severe systolic dysfunction.
Times cited: 11
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
American Heart Journal.
Times cited: 63